Table 2.
Patients With Cancer and CHD Diagnosed Between 1999 and 2013 With Updated Smoking Status Who Were Advised to Quit and Prescribed Smoking Cessation Medication Within the First Year After Diagnosis
| Smokers and <3-y Ex-Smokers (All Cancer, n=12,393; CHD, n=12,393)a | Current Smokers Only (All Cancer, n=10,794; CHD, n=10,794)b | ≥1-y Survivors Only (All Cancer, n=4,228; CHD, n=4,228)c | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| Outcome | Cancer No. (%) | CHD Control No. (%) | OR (95% CI) | Cancer No. (%) | CHD Control No. (%) | OR (95% CI) | Cancer No. (%) | CHD Control No. (%) | OR (95% CI) |
| Updated smoking status | |||||||||
| All cancers | 4,541 (37) | 9,627 (78) | 0.18 (0.17–0.19) | 3,962 (37) | 8,437 (78) | 0.18 (0.17–0.19) | 2,605 (62) | 3,611 (86) | 0.26 (0.23–0.29) |
| Lung cancer | 2,873 (31) | 7,224 (77) | 0.14 (0.13–0.15) | 2,454 (31) | 6,253 (78) | 0.13 (0.12–0.14) | 1,404 (60) | 1,982 (84) | 0.25 (0.22–0.29) |
| Bladder cancer | 1,172 (57) | 1,620 (79) | 0.38 (0.33–0.44) | 1,055 (57) | 1,466 (79) | 0.38 (0.33–0.44) | 851 (65) | 1,138 (87) | 0.28 (0.22–0.34) |
| Upper aerodigestive tract cancer | 496 (50) | 783 (79) | 0.27 (0.22–0.33) | 453 (50) | 718 (79) | 0.27 (0.22–0.33) | 350 (61) | 502 (87) | 0.23 (0.17–0.30) |
| Advice to quit | |||||||||
| All cancers | 2,794 (23) | 5,601 (45) | 0.38 (0.36–0.40) | 2,636 (24) | 5,245 (48) | 0.36 (0.34–0.38) | 1,630 (39) | 2,156 (51) | 0.60 (0.55–0.66) |
| Lung cancer | 1,672 (18) | 4,196 (45) | 0.28 (0.26–0.30) | 1,564 (19) | 3,907 (49) | 0.26 (0.24–0.28) | 810 (34) | 1,182 (50) | 0.49 (0.43–0.56) |
| Bladder cancer | 809 (39) | 925 (45) | 0.87 (0.76–0.99) | 774 (42) | 880 (48) | 0.86 (0.75–0.98) | 594 (46) | 669 (51) | 0.84 (0.70–0.99) |
| Upper aerodigestive tract cancer | 313 (31) | 480 (48) | 0.50 (0.41–0.60) | 298 (33) | 458 (50) | 0.50 (0.41–0.60) | 226 (39) | 305 (53) | 0.58 (0.46–0.74) |
| Prescriptions | |||||||||
| All cancers | 1,504 (12) | 2,560 (21) | 0.67 (0.63–0.73) | 1,439 (13) | 2,426 (22) | 0.67 (0.62–0.72) | 882 (21) | 967 (23) | 1.05 (0.94–1.17) |
| Lung cancer | 989 (11) | 1,950 (21) | 0.58 (0.53–0.63) | 940 (12) | 1,835 (23) | 0.57 (0.52–0.63) | 498 (21) | 547 (23) | 1.06 (0.91–1.23) |
| Bladder cancer | 291 (14) | 386 (19) | 0.96 (0.81–1.16) | 279 (15) | 373 (20) | 0.97 (0.81–1.16) | 226 (17) | 280 (22) | 1.02 (0.83–1.25) |
| Upper aerodigestive tract cancer | 224 (22) | 224 (22) | 1.00 (0.80–1.24) | 220 (24) | 218 (24) | 1.03 (0.83–1.29) | 158 (27) | 140 (24) | 1.18 (0.89–1.55) |
CHD = coronary heart disease; UAT = upper aeordigestive tract.
a
Cancer subgroup patients and 1-to-1 matched CHD control patients: lung, n = 9,347; bladder, n = 2,050; UAT, n = 996.
b
Cancer subgroup patients and 1-to-1 matched CHD control patients: lung, n = 8,037; bladder, n = 1,848; UAT, n = 909.
c
Cancer subgroup patients and 1-to-1 matched CHD control patients: lung, n = 2,350; bladder, n =1,302; UAT, n = 576.